Company Snapshot: Retrophin, Inc.
Retrophin, Inc. (NASDAQ: RTRX) is a publicly-traded, New York-based biopharmaceutical company focused on the discovery, acquisition, development and commercialization of drugs for the treatment of debilitating and often life-threatening diseases for which there are currently limited patient options. The Company is currently focused on several catastrophic diseases affecting children, including Focal Segmental Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated Neurodegeneration (PKAN), Duchenne Muscular Dystrophy and others. Retrophin has begun enrollment in a potentially pivotal Phase 2 clinical trial of its lead compound, sparsentan, for FSGS. The Company also intends to reintroduce Syntocinon Nasal Spray (oxytocin) in the U.S. to assist initial postpartum milk ejection and also initiate clinical trials for the drug as a potential treatment for schizophrenia and autism. Retrophin plans to initiate a Phase 1 pharmacokinetic trial of RE-034, an ACTH analog, in the first half of 2014.
- Jul 12 2018 Retrophin to Report Second Quarter 2018 Financial Results
- Jun 14 2018 Retrophin Announces Expansion of Intellectual Property Estate for Sparsentan with Newly Issued U.S. Patent
- Jun 4 2018 Retrophin Announces Pivotal Phase 3 FORT Study of Fosmetpantotenate in PKAN Opens Enrollment to Pediatric Patients
- May 24 2018 Retrophin to Present at Upcoming Investor Conferences